Re-reading "The Emperor of All Maladies."
The book chronicles the history of cancer treatment — the tragic yet heroic scientific breakthroughs, the price paid for venturing into uncharted territory. The descriptions of toxic reactions caused by the misuse of VAMP combination therapy (vinca alkaloids, methotrexate, mercaptopurine, and others) are particularly unsettling.
Drugs are a symbol of progress, yet their misuse exposes how poorly we grasp the complexity of disease and treatment. These words still sting today.
In the 1950s, chemotherapy drugs carried enormous hope. VAMP showed remarkable efficacy in certain leukemia patients, and scientists must have felt they were wielding a sharp sword that could cut through death's door. But the sword had no scabbard — it targeted cell proliferation, killing cancer cells but sparing no rapidly dividing normal cells either. Bone marrow, intestinal epithelium, hair follicle cells — none escaped.
A slight miscalculation in dosage could lead to severe immunosuppression, hemorrhagic enteritis, and even death from the treatment itself.
The doctors and scientists of that era had good intentions. Medical knowledge and technology simply had not caught up with their enthusiasm. They lacked systematic understanding of drug dosage, metabolic pathways, and long-term toxicity.
The line between saving a life and harming one sometimes came down to a single number.
Pharmacovigilance and Modern Medicine
It was precisely because of these historical lessons that drug safety gained increasing attention.
The term pharmacovigilance traces its origins to the 1961 thalidomide disaster. After that catastrophe, it gradually emerged as a discipline dedicated to one thing: monitoring, evaluating, and controlling risks throughout the drug use process.
Its core tasks can be summarized in four points:
- Monitoring adverse reactions — collecting adverse reaction reports from patients, analyzing patterns and risk factors, and identifying potential problems.
- Assessing risk and benefit — every drug has side effects. The key question is whether these risks are outweighed by clinical benefits. (In plain terms: is it worth it?)
- Refining prescribing guidance — revising dosage recommendations, contraindications, and interaction warnings based on findings, providing safer options for doctors and patients.
- Preventing misuse and dependence — antibiotic resistance is a living example; overuse harms more than just one person.
In the modern healthcare system, pharmacovigilance is no longer an optional appendage. It is an essential component running through the entire lifecycle of drug development, approval, and post-market surveillance. With the rise of precision medicine, individualized treatment has gradually become a reality, and pharmacovigilance has shifted from "average risk" assessment to "individual risk" analysis — genetic differences, comorbidities, environmental factors, all factored in.
The WHO Programme for International Drug Monitoring
In 1963, the World Health Assembly passed a resolution to accelerate the dissemination of adverse drug reaction information. In 1968, the WHO launched the Programme for International Drug Monitoring, gradually expanding it worldwide. Today, over 140 countries participate.
The Uppsala Monitoring Centre serves as the core institution of this program, responsible for collecting, analyzing, and evaluating adverse reaction reports submitted by member countries and feeding the results back. The formation of this network has truly set international cooperation in drug safety in motion. That said, there are considerable differences among countries in the implementation and maturity of pharmacovigilance — some are quite well-developed, others are still finding their footing.
The United States follows a centralized model — the FDA's Center for Drug Evaluation and Research oversees everything. The advantage is centralized data and efficient processing. The organizational structure, legal framework, information disclosure, and feedback mechanisms are relatively mature. The FDA's internal pharmacovigilance bodies include the Office of Surveillance and Epidemiology, the Office of New Drugs, the Office of Executive Programs, and the Drug Safety Oversight Board, each with defined responsibilities and coordinated operations. As the global leader in drug regulation, this model has been emulated by many countries.
The European Union has taken a regulatory approach. Through the implementation of pharmacovigilance legislation (EC No. 726/2004), all new drugs must be accompanied by detailed pharmacovigilance documentation and a risk management system. The EMA has the authority to impose additional requirements after drug approval, and sponsors must submit periodic suspected adverse reaction reports and assess the risk-benefit balance of their products. Certain products must also submit an EU-RMP (EU Risk Management Plan), and any changes in post-market application trigger a reassessment.
Each country has taken a different path, but the goal is the same: safeguarding public drug safety.
Final Thoughts
Looking back at history, the tragedies of drug misuse often stemmed from excessive optimism about science and technology. Pharmacovigilance, at its core, is a humble acknowledgment of the limits of human understanding.
When it comes to drugs, we need both hope and vigilance.
Reap the benefits, guard against the harm. Everyone understands this in principle — putting it into practice is another matter entirely.